Newsletter - July 2015


Hello Isomark Friends and Partners,

2015 has proven to be a bustling year so far for the Isomark team.  We have made strides with our second-generation device development, continued to fill our current investment round, applied for multiple grant opportunities, and launched a new, multi-center clinical study.

In this newsletter we focus on our newly launched study, the addition of a new medical advisor, and update you on recent developments with our device.


Joe Kremer, CEO


A few times each year we will update you on our progress.  In between newsletters, please visit our website,, for the most up-to-date information.



Expanding Research to Florida

New partnerships allowing for increased study.

With subjects enrolling at the University of Wisconsin Hospital and Clinics, Isomark has launched a multi-center clinical trial at two sites in Florida. Both the University of Florida - Gainesville and Jacksonville have a large patient population and a strong focus on surgery and trauma patients. 

Recently, the University of Florida - Gainesville was awarded a $12 million, five-year grant from the NIH to establish a Sepsis and Critical Illness Research Center.  The center will study long-term outcomes in patients treated for sepsis in the surgical and trauma ICUs at UF Health Shands Hospital, with the goal of developing clinical solutions for sepsis as well as illnesses that stem from it and their enduring, dismal effects.



Isomark Welcomes Dr. Maki

A veteran of the infection prevention field. is pleased to announce the addition of Dr. Dennis Maki as a new medical advisor.  Dr. Maki is currently the Ovid O. Meyer Professor of Medicine in the Divisions of Infectious Diseases and Pulmonary-Critical Care Medicine at the University of Wisconsin School of Medicine and Public Health, attending physician in the UWHC Center for Trauma and Life Support and eICU, and former Head of the Division of Infectious Diseases from 1979-2007.

Dr. Maki's research has focused on the prevention and management of hospital-acquired and life-threatening infections.  Through his career, Dr. Maki has published more than 250 original papers and 700 abstracts of research presented at scientific meetings, both national and international.  On top of that, Dr. Maki's publications have been cited by other researchers more than 16,000 times.  He has received numerous awards, certifications, and has served on multiple advisory boards, including the CDC, NIH, and HHS.



Device Development

Size (and cost) matters.
Isomark's laser spectroscopy team has adapted a carbon isotopic spectrometer, one originally developed for a Mars mission, to our needs and are continuing to make iterative steps at reducing size and cost.  Isomark and its partners have developed a foam model (right) of the new Canary™.

As Isomark continues to work with partners to develop a smaller and less expensive Canary, our firmware designer has been diligently working to create an easy-to-use and intuitive graphical user interface (GUI).  The GUI will serve as a means of communicating with and controlling the device.

Much of the device development is funded by a $1.7 million NIH SBIR grant.



Isomark's patented non-invasive breath technology may allow for the early detection of infection.

Isomark's technology is under development and not available for use.  To stay up to date, be sure to watch our website and follow us online.





Want to learn more?  Don't be shy.
455 Science Drive, Suite 155
Madison, WI  53711
(608) 561-1895

Copyright © 2015 Isomark, LLC, All rights reserved.